Samsung Bioepis gets EC's approval for Opuviz

Opuviz is the second EC-approved ophthalmology biosimilar under Samsung Bioepis and the US-based Biogen’s partnership

The headquarters of Samsung Bioepis
The headquarters of Samsung Bioepis
Dae-Kyu Ahn 1
2024-11-19 14:18:01 powerzanic@hankyung.com
Bio & Pharma


South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European Commission (EC) approved Opuviz (Aflibercept), its biosimilar to Beyer’s Eylea for the treatment of various eye diseases.

Opuviz is the second ophthalmology biosimilar approved in Europe and the fifth biosimilar in the portfolio developed by Samsung Bioepis with commercialization rights held by Biogen.

In November 2019, Samsung Bioepis and Biogen announced that they had entered a commercialization agreement for two ophthalmology biosimilar candidates, Byooviz and Opuviz in the US, Canada, and Europe. 

Eylea, which generates global annual sales of about 12 trillion won ($9 billion), is used to treat wet age-related macular degeneration (AMD) and other retinal conditions by binding to vascular endothelial growth factor (VEGF) and inhibiting abnormal blood vessel growth.

AMD, which damages the central neural tissue of the retina, can cause severe vision impairment and blindness without ongoing treatment.

Opuviz was approved in the US in May and is marketed in South Korea as Afilivu through its partner Samil Pharmaceutical.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com

Samsung Bioepis leads in Soliris biosimilar market in Europe

Samsung Bioepis leads in Soliris biosimilar market in Europe

Samsung Bioepis booth at ERA 2024, the leading European nephrology conference held in Stockholm between May 23-26, 2024. (Courtesy of Samsung Bioepis) STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Soliris for the treatment of patients with rare, life-threatening disease paroxysmal noctu

Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara. This approval came two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) issued

Samsung Bioepis to supply Hadlima to US government

Samsung Bioepis to supply Hadlima to US government

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and development unit, have secured a bid to supply its biosimilar Hadlima (adalimumab-bwwd), a treatment for autoimmune diseases, to the US Department of Vetera

Samsung Bioepis gets FDA OK for its interchangeable biosimilar

Samsung Bioepis gets FDA OK for its interchangeable biosimilar

Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official designation from the US Food and Drug Administration (FDA) as interchangeable with the original medicine. Samsung Bioepis is thus South Korea’s fi

(* comment hide *}